RGBP (Regen BioPharma) Days Payable: 0.00 (As of Mar. 2026)

What is Regen BioPharma Days Payable?

Regen BioPharma RGBP +33.33% Days Payable is 0.00 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 707 Biotechnology companies, Regen BioPharma ranks worse than 141442.57% on this metric.

Regen BioPharma's average Accounts Payable for the three months ended in Mar. 2026 was $0.02 Mil. Regen BioPharma's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Regen BioPharma's Days Payable or its related term are showing as below:

RGBP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Regen BioPharma's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Regen BioPharma Days Payable Related Terms

Regen BioPharma Days Payable Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Days Payable Chart

Regen BioPharma Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Days Payable

Get a 7-Day Free Trial

0.00

Regen BioPharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

RGBP vs ENDV, ADTX, SCPX: Days Payable Comparison

For the Biotechnology subindustry, Regen BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Days Payable falls into.

Save Embed

Regen BioPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Regen BioPharma's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as

	Days Payable (A: Sep. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Sep. 2024 )	+	Accounts Payable (A: Sep. 2025 ))	/	count )	/	Cost of Goods Sold (A: Sep. 2025 )	*	Days in Period
=	( (0.03	+	0.002)	/	2 )	/	0	*	365
=	0.016					/	0	*	365
=	N/A

Regen BioPharma's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.011	+	0.02)	/	2 )	/	0	*	365 / 4
=	0.0155					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Regen BioPharma (RGBP) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 707 companies in the Biotechnology industry.

Is Regen BioPharma's Days Payable too high?

Regen BioPharma's current Days Payable is 0.00. Based on the distribution chart, Regen BioPharma ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.

How does Regen BioPharma's Days Payable compare to ENDV and ADTX?

According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 707 companies for Days Payable. This places Regen BioPharma in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Regen BioPharma stock overvalued right now?

Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ENDV ADTX SCPX IOBTQ CNBX SIGY CARM CYTOF LIPO WINT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RGBPP.PFD:USA

Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942

Website https://www.regenbiopharmainc.com

Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.